Compare IDEXX Laboratories, Inc. (IDXX) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is the larger of the two by market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 2,892,221). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| IDXX | VCSH | |
|---|---|---|
Market Cap | $40.43B | $51.90B |
Volume | 692,164 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $766.68 | $80.20 |
52-Week Low | $504.70 | $77.03 |
Typical Hold Time | 46 Days | 52 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
VCSH trades at $77.285 with minimal daily movement (+0.02%), showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains a competitive 4.5% dividend yield with a low 0.03% expense ratio, though recent analysis suggests credit spreads appear tight. Recent institutional activity shows mixed positioning with both stake increases and reductions reported.
The short-term corporate bond ETF faces headwinds from potential rate environment shifts while offering higher yields than treasury alternatives. Limited price appreciation potential exists given current technical positioning and market expectations of sustained rates, making it suitable for income-focused investors comfortable with corporate credit risk exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
